Evaluation of Severity in Juvenile Dermatomyositis and Adult-onset Dermatomyositis: a National Multicentric Retrospective Study

Status: Recruiting
Location: See location...
Intervention Type: Other
Study Type: Observational
SUMMARY

Dermatomyositis (DM) are rare and heterogeneous systemic autoimmune diseases, characterized by the association of muscle inflammation, skin inflammation and vasculopathy. DM concern both adults and children. DM can be life-threatening (interstitial lung disease, infectious complications) and responsible of significant functional disability (muscle weakness). Age of onset appear to be an independent prognostic factor. Juvenile-onset DM is characterized by a higher frequency of calcinosis, skin ulceration and digestive vasculitis. In adults, interstitial lung disease and cancer are more frequent with higher mortality. Data concerning the comparison of the initial severity between juvenile and adult-onset DM are limited. The main objective is to compare global severity between juvenile DM and adult-onset DM at initial diagnosis. Secondary objectives are: * to compare organ-specific severity between juvenile DM and adult-onset DM at diagnosis. * to compare damage during follow-up and at last follow-up between juvenile DM and adult-onset DM. * to compare activity at the last follow-up between juvenile DM and adult-onset DM. * to compare iatrogenic complications between juvenile DM and adult-onset DM.

Eligibility
Participation Requirements
Sex: All
View:

• Patient with dermatomyositis according to 2017 American College of Rheumatology (ACR)/ European Alliance of Associations for Rheumatology (EULAR) classification

Locations
Other Locations
France
Chu Nancy
RECRUITING
Nancy
Contact Information
Primary
Paul Decker, MD
p.decker@chru-nancy.fr
+33383157240
Time Frame
Start Date: 2023-10-01
Estimated Completion Date: 2024-09-30
Participants
Target number of participants: 200
Treatments
Juvenile dermatomyositis
Dermatomyositis before 18 years-old
Adult-onset dermatomyositis
Dermatomyositis from 18 years-old
Sponsors
Leads: Central Hospital, Nancy, France

This content was sourced from clinicaltrials.gov

Similar Clinical Trials